Status:

NOT_YET_RECRUITING

A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

Lead Sponsor:

Incyte Corporation

Conditions:

Solid Tumors

Hematologic Malignancies

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

A study to evaluate the safety and tolerability of INCA036873 in participants with advanced solid tumors and hematological malignancies.

Eligibility Criteria

Inclusion

  • Age ≥18 years.
  • ECOG performance status of 0 or 1.
  • Histologically confirmed:
  • Clear cell renal cell carcinoma (ccRCC).
  • Diffuse large B-cell lymphoma (DLBCL, NOS).
  • High-grade B-cell lymphoma (HGBCL).
  • Peripheral T-cell lymphoma (PTCL, incl. NOS and ALCL).
  • Cutaneous T-cell lymphoma (CTCL, incl. MF or SS ≥Stage IIB with B0/B1 blood involvement).
  • Disease progression, relapse, or refractory to prior therapy:
  • ccRCC: ≥1 prior line incl. ICI + TKI.
  • DLBCL/HGBCL: ≥2 prior lines incl. immunochemotherapy and salvage.
  • PTCL/CTCL: ≥1 prior systemic therapy.
  • Measurable disease by RECIST v1.1 (ccRCC), Lugano 2014 (lymphomas), or ISCL/USCLC/EORTC (CTCL).
  • Tumor tissue available for central testing.

Exclusion

  • Untreated or progressive CNS disease unless previously treated and stable.
  • Other active invasive malignancy within 2 years (except certain low-risk cancers).
  • Prior CD70-targeting therapy, including CAR T.
  • ASCT or CAR T ≤12 weeks before enrollment; prior organ or allogeneic transplant.
  • Unresolved ≥Grade 2 toxicity from prior therapy (with exceptions).
  • Primary immunodeficiency or active autoimmune disease requiring immunosuppression.
  • Active HBV, HCV, HIV, or other chronic infections requiring systemic therapy.
  • Pregnancy, breastfeeding, or unwillingness to use effective contraception.
  • Other protocol-defined Inclusion/Exclusion Criteria may apply.

Key Trial Info

Start Date :

December 31 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

August 18 2028

Estimated Enrollment :

280 Patients enrolled

Trial Details

Trial ID

NCT07195916

Start Date

December 31 2025

End Date

August 18 2028

Last Update

October 15 2025

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies | DecenTrialz